Public health response to an anthrax attack: AN evaluation of vaccination policy options

Biosecurity and Bioterrorism

Volumn 5, Issue 1, 2007, Pages 26-34

  Baccam, Prasith ^a,c   Boechler, Michael ^b  

^a IEM Inc   (United States)

^b IEM Inc   (United States)

^c IBM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; EVALUATION; HUMAN; IMMUNOLOGY; MANAGEMENT; PUBLIC HEALTH; THEORETICAL MODEL;

ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; BIOTERRORISM; HUMANS; MODELS, THEORETICAL; POLICY MAKING; PUBLIC HEALTH;

EID: 34248648502     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2006.0001     Document Type: Article

References (22)

1. World Health Organization. Health Aspects of Chemical and Biological Weapons. Geneva: World Health Organization; 1970.
2. U.S. Congress, Office of Technology Assessment. Proliferation of Weapons of Mass Destruction. Washington, DC: Office of Technology Assessment; 1993. Publication OTA-ISC-559.
3. Centers for Disease Control and Prevention. Notice to readers: use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51(45): 1024-1026.
4. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Nat Acad Sci 2003; 100:10129-10132.
5. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Nat Acad Sci 2003;100:4346-4351.
6. Investigation of terrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb Mortal Wkly Rep 2001;50:909-919.
7. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-2252.
8. Bartlett JG, Inglesby TV, Borio L. Management of anthrax. Clin Inf Dis 2002;35:851-858.
9. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001;2:233-247.
10. Lucey D. Anthrax (biodefense). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier, Churchill, Livingstone; 2005:3618-3624.
11. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorismrelated inhalational anthrax: the first 10 cases reported in the United States. Emerg Inf Dis 2001;7:933-944.
12. Brookmeyer R, Johnson E. Computer program to evaluate public health policy options in response to an anthrax outbreak: the impact of post exposure antibiotics and vaccine. Baltimore, Md: Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health; January 2004.
13. Wilkening DA. Sverdlovsk revisited: modeling human inhalational anthrax. Proc Nat Acad Sci 2006;103:7589-7594.
14. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature 2004;432:901-904.
15. Doolan DL, Freilich DA, Brice GT, et al. The US capital bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007;195:174-184.
16. Wein LM, Craft DL. Evaluation of public health interventions for anthrax: a report to the secretary's council on Public Health Preparedness. Biosecur Bioterror 2005;3:348-356.
17. Centers for Disease Control and Prevention. Cities Readiness Initiative Guidance. Appendix 3. Atlanta: Centers for Disease Control and Prevention; 2004. Available at: http://www. bt.cdc.gov/planning/guidance05/pdf/ appendix3.pdf. Accessed November 9, 2006.
18. Plotkin SA, Brachman PS, Utell M, Bumford FH, Atchison MM. An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. Am J Med 1960; 112: 4-12.
19. Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003;163:701-709.
20. Lempert RJ, Popper S, Bankes SC. Shaping the Next One Hundred Years: New Methods for Quantitative, Long-Term Policy Analysis. Santa Monica, Calif: RAND; 2003.
21. Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med 2005;142:601-610.
22. Hupert N, Mushlin AI, Callahan MA. Modeling the public health response to bioterrorism: using discrete event simulation to design antibiotic distribution centers. Med Decis Making 2002;22:1-9.